Enjoy complimentary customisation on priority with our Enterprise License!
The Blood Plasma Market size is forecast to increase by USD 15.9 billion, at a CAGR of 8.6% between 2023 and 2028. The market is witnessing significant growth due to the increasing prevalence of primary immunodeficiency and secondary immunological deficits, leading to a higher demand for plasma-derived therapies such as immunoglobulins for treating various chronic diseases. The market is also driven by the expanding use of personalized medicine and orphan drug designations for rare diseases, which are expected to boost the growth of the market. Innovative solutions, including the use of microbial enzymes in blood transfusion technology, are addressing the global blood shortage crisis, further fueling market growth. However, challenges such as the closure of plasma donation centers due to operational network issues and regulatory restrictions on plasma collection may hinder market growth. Key diseases driving the market include immunodeficiency diseases such as Hemophilia A and Hemophilia B, for which plasma-derived therapies like Hyperimmune globulin are essential. Clinical trials are ongoing to explore the potential of plasma-derived therapies in treating various chronic diseases, further boosting market growth.
Request Free Blood Plasma Market Sample
The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD billion" for the period 2024-2028, as well as historical data from 2018 - 2022 for the following segments.
The therapeutic use segment is estimated to witness significant growth during the forecast period. Platelet-rich plasma (PRP), a preparation derived from a patient's own blood, has gained significant traction in various medical fields, including Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, and Immunology. PRP's applications extend beyond cosmetic procedures, such as vampire facials and hair growth treatments. In the realm of healthcare, PRP is increasingly utilized for medical purposes, particularly in the treatment of blood disorders like Hypogammaglobulinemia and Immunodeficiency Diseases, including Hemophilia.
Get a glance at the market share of various regions Download the PDF Sample
The therapeutic use segment was valued at USD 16.1 billion in 2018. Hospitals and clinics are integrating PRP into their offerings due to its safety, cost-effectiveness, and natural composition. In Gynecology, PRP serves as an adjunct treatment for conditions such as thin endometrium, premature ovarian failure, urinary incontinence, genitourinary fistulas, and Asherman syndrome. PRP's therapeutic potential lies in its rich growth factors and proteins, which facilitate the regeneration and repair of damaged cells, tissues, and organs. The patient epidemiology for these conditions necessitates the expansion of PRP applications in healthcare, making it a valuable resource for medical professionals.
For more insights on the market share of various regions Request Free Sample
North America is estimated to contribute 47% to the growth of the global market during the forecast period. Technavio's analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period. The North American market is experiencing notable progress and strategic initiatives, particularly in the realm of dried plasma. Notably, Canadian Blood Services, in collaboration with the Department of National Defence, is leading a project starting in July 2024 to reintroduce dried plasma, an essential component in battlefield medicine. This endeavor, supported by Veterans Affairs Canada, aims to improve the safety and production of dried blood plasma, utilizing historical freeze-drying technology from the Second World War. Dried plasma presents several logistical advantages over frozen plasma, including a shelf life of up to four years at room temperature, compared to one year for frozen plasma. This extended shelf life can significantly enhance the accessibility and availability of plasma in various medical fields such as Pulmonology, Rheumatology, Transplantation, Neurology, Hematology, and the treatment of Immunodeficiency Diseases like Hypogammaglobulinemia and Hemophilia. Hospitals and clinics stand to benefit from this development, ensuring a consistent and reliable supply of plasma for their patients.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
ADMA Biologics Inc. - The company offers blood plasma products such as Bivigam -Immunoglobulin, Nabi-HB -Clotting Factor and others.
Technavio provides the ranking index for the top 20 companies along with insights on the market positioning of:
Explore our company rankings and market positioning Request Free Sample
|
Market structure |
Fragmented |
|
YoY growth 2023-2024 |
8.4 |
The market is witnessing significant growth due to the increasing prevalence of primary immunodeficiency and secondary immunological deficits, leading to a higher demand for plasma-derived therapies such as immunoglobulins for treating various chronic diseases. The market is also driven by the expanding use of personalized medicine and orphan drug designations for rare diseases, which are expected to boost the growth of the market. Innovative solutions, including the use of microbial enzymes in blood transfusion technology, are addressing the global blood shortage crisis, further fueling market growth. However, challenges such as the closure of plasma donation centers due to operational network issues and regulatory restrictions on plasma collection may hinder market growth. Key diseases driving the market include immunodeficiency diseases such as Hemophilia A and Hemophilia B, for which plasma-derived therapies like Hyperimmune globulin are essential. Clinical trials are ongoing to explore the potential of plasma-derived therapies in treating various chronic diseases, further boosting market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Innovative solutions targeting the global blood shortage crisis is notably driving market growth. The market encompasses a range of essential blood components, including Hyperimmune Globulins, Albumin, Factor VIII, and Factor IX, which find extensive applications in Infusion Solutions, Gels, Sprays, Biomedical Sealants, and therapeutic indications across Immunology and Oncology. However, despite the significant advancements in this field, there remains a pressing issue of unmet clinical needs in numerous regions, with an estimated 3.5 billion people residing in areas referred to as "blood deserts," where access to blood components is inadequate in at least 75% of cases. To address this critical challenge, the Blood D.E.S.E.R.T Coalition, spearheaded by researchers from Harvard Medical School and Brigham and Women's Hospital, has proposed innovative solutions.
These strategies include the implementation of civilian walking blood banks, modeled after military practices, where community volunteers are prepared to donate blood on short notice, thereby reducing reliance on central storage, particularly in rural areas. Another promising approach is the utilization of intraoperative auto-transfusion, a technique where a patient's own blood is collected and reused during surgical procedures, thereby minimizing the demand for external blood supplies. Thus, such factors are driving the growth of the market during the forecast period.
Expanding the use of microbial enzymes in blood transfusion technology is the key trend in the market. The market is experiencing significant advancements, particularly in the production of specialized blood products such as Hyperimmune Globulins, Albumin, Factor VIII, and Factor IX. These infusion solutions are derived from human plasma and contain high concentrations of specific antibodies or clotting factors, making them essential in various therapeutic indications, including immunology and oncology. Moreover, plasma derivatives have diverse applications beyond transfusion therapy. For instance, Immunoglobulin is used as a biomedical sealant for surgical procedures, while Factor VIII and Factor IX are available in gels and sprays for topical application. These innovations expand the market's scope and provide significant benefits to patients. Recent research in blood transfusion technology has shown promising results in creating universal blood suitable for all recipients using microbial enzymes. A Scandinavian collaboration has been at the forefront of this development, leveraging enzymes derived from gut bacteria to effectively remove A and B antigens from red blood cells. This breakthrough could revolutionize the field of transfusion medicine and organ transplantation.
Human blood types are determined by the presence of specific enzymes encoded by the ABO gene. The A gene produces N-acetylgalactosaminyl-transferase, while the B gene produces -galactosyltransferase. These enzymes add A-and B-specific sugars to the glycolipids and glycoproteins in red blood cells. By removing these antigens, universal blood could potentially eliminate the need for extensive blood typing and matching, making transfusions safer and more accessible. In summary, the market is undergoing transformative changes with the advent of microbial enzymes in blood transfusion technology. The development of universal blood and the diverse applications of plasma derivatives are expanding the market's potential and offering significant benefits to patients in various therapeutic areas. Thus, such trends will shape the growth of the market during the forecast period.
Closure of plasma donation centers due to operational network issues is the major challenge that affects the growth of the market. In the intricate realm of biomedical sciences, the market holds significant importance due to its role in producing essential products such as Hyperimmune Globulins, Albumin, Factor VIII, and Factor IX. These infusion solutions, derived from human plasma, serve therapeutic indications in various fields, including immunology and oncology. The production process involves converting plasma into gels or sprays for further manufacturing. However, the industry faces potential operational challenges. For instance, in April 2024, Octapharma Plasma encountered a significant IT network issue that led to the closure of 195 plasma collection centers across 35 states in the U.S., including three in Columbus, Ohio.
This disruption underscores the critical vulnerability of the plasma industry to technological complications, which can have far-reaching consequences on plasma collection and supply. Plasma, which comprises approximately 55% of human blood and is essential for transporting antibodies, proteins, enzymes, and clotting factors, is collected primarily at these centers. Consequently, any disruption to their operations can significantly impact the production and distribution of these vital biomedical products. Hence, the above factors will impede the growth of the market during the forecast period.
The market forecasting report includes the adoption lifecycle of the market research and growth, covering from the innovator's stage to the laggard's stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their market growth analysis strategies.
Customer Landscape
Blood plasma is a vital component of the blood, making up around 55% of the total blood volume. It is a source of essential proteins, including clotting factors, immunoglobulins, and albumin. Plasma plays a crucial role in various therapeutic indications such as immunology, oncology, pulmonology, rheumatology, transplantation, neurology, hematology, and liver disease. Plasma-derived products like immunoglobulins, coagulation factors, and albumin find extensive applications in treating bleeding disorders, immunodeficiencies, and infectious diseases. Plasma donors are essential for the production of these life-saving products. Plasma collection involves separating the plasma from the blood constituents like red blood cells, white blood cells, and platelets. Plasma is used in various forms, including infusion solutions, gels, sprays, biomedical sealants, and therapeutic drugs.
The market is driven by the increasing prevalence of chronic diseases, rising geriatric population, and clinical trials for rare diseases. The market is segmented based on therapeutic indication, plasma-derived products, and geography. The key applications of plasma-derived products include the treatment of hemophilia, hypogammaglobulinemia, immunodeficiency diseases, and secondary immunological deficits. The market is expected to witness significant growth due to the increasing demand for personalized medicine and orphan drug designations. However, the market may face challenges due to side effects, allergic conditions, and the high cost of plasma-derived products. The market is also expected to witness significant developments in the non-therapeutic application of plasma, such as burn treatment, shock treatment, and trauma patients.
|
Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
201 |
|
Base year |
2023 |
|
Historic period |
2018 - 2022 |
|
Forecast period |
2024-2028 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 8.6% |
|
Market Growth 2024-2028 |
USD 15.9 billion |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 47% |
|
Key countries |
US, Germany, France, China, Canada, UK, Japan, Brazil, India, and Italy |
|
Competitive landscape |
Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
ADMA Biologics Inc., Bio Products Laboratory Ltd., Biotest AG, CSL Ltd., GC Biopharma Corp., Grifols SA, Kamada Ltd., Kedrion SpA, LFB SA, Meiji Holdings Co. Ltd., Octapharma AG, Pfizer Inc., Sanquin, SK Plasma Co. Ltd., and Takeda Pharmaceutical Co. Ltd. |
|
Market dynamics |
Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, AI impact on market trends, COVID -19 impact and recovery analysis and future consumer dynamics, market condition analysis for the market forecast period |
|
Customization purview |
If our market report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
1 Executive Summary
2 Technavio Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Application
9 Market Segmentation by Source
10 Customer Landscape
11 Geographic Landscape
12 Drivers, Challenges, and Opportunity/Restraints
13 Competitive Landscape
14 Competitive Analysis
15 Appendix
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
